nutlin-3a profile

nutlin 3: an MDM2 antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11433190
CHEMBL ID	191334
CHEBI ID	95096
SCHEMBL ID	1155752
MeSH ID	M0510642

Synonym
HY-10029
nutlin-3
nutlin 3
nutlin-3a ,
(4s,5r)-nutlin-3
4-((4s,5r)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1h-imidazole-1-carbonyl)piperazin-2-one
(rac)-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl)(piperazin-1-yl)methanone
bdbm50229787
rac-4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1h-imidazole-1-carbonyl)piperazin-2-one
4-[(4s,5r)-4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one
nsc-732664
CHEMBL191334 ,
nsc 732664
53ia0v845c ,
unii-53ia0v845c
BCP9001003
675576-98-4
(+)-nutlin-3
4HG7
4J3E
CS-0296
(-)-nutlin 3
4-(((4s,5r)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl)carbonyl)piperazin-2-one
rebemadlin
sml-0580
rebemadlin [inn]
S8059
nutlin 3a
l7c92ioe65 ,
2-piperazinone, 4-(((4s,5r)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-(4-methoxy-2-(1-methylethoxy)phenyl)-1h-imidazol-1-yl)carbonyl)-
unii-l7c92ioe65
SCHEMBL1155752
2-piperazinone, 4-(((4r,5s)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-(4-methoxy-2-(1-methylethoxy)phenyl)-1h-imidazol-1-yl)carbonyl)-, rel-
4-[[(4s,5r)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1h-imidazol-1-yl]carbonyl]-2-piperazinone
nutlin-3, (-)-
BDUHCSBCVGXTJM-WUFINQPMSA-N
4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4, 5-dihydro-1h-imidazole-1-carbonyl)piperazin-2-one
HMS3649P17
4-[(4s,5r)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
nutlin 3b
nutlin (3a)
EX-A1359
AKOS027422740
CHEBI:95096
nutlin-3a chiral
(-)-nutlin-3
(?)-nutlin-3
4-[(4s,5r)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1h-imidazole-1-carbonyl]piperazin-2-one
AS-75148
nutlin-3a, >=98% (hplc)
AC-35379
NCGC00344347-05
nutlin3a
Q27166862
(+/-)-4-[4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one
548472-68-0 (4r5s, and 4s5r)
mfcd14636430
SR-01000946691-1
sr-01000946691
4-[cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1h-imidazole-1-carbonyl]piperazin-2-one
675576-98-4 (4s5r)
nsc763443
nsc-763443
nsc-756875
nsc-756876
nsc756876
nsc756875
(-)-4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1h-imidazole-1-carbonyl)piperazin-2-one
DTXSID801317967
4-[(4s,5r)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one
Z2037279564

Excerpt	Reference	Relevance
" Collectively, these results demonstrate that the induction of p53 peri-operatively protects bone healing from the toxic effects of CDP, while maintaining OS toxicity."	( Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. Aronson, J; Becton, DL; Bunn, RC; Liu, L; Lumpkin, CK; Montgomery, CO; Nicholas, RW; Skinner, RA; Stine, KC; Suva, LJ; Swearingen, CJ; VanderSchilden, J; Wahl, EC, 2016)	0.43

Excerpt	Reference	Relevance
" We used physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of nutlin-3a in the mouse."	( Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Boulos, N; Dyer, MA; Guy, RK; Lu, M; Mallari, J; Miller, L; Nemeth, K; Panetta, JC; Roussel, MF; Stewart, CF; Tagen, M; Throm, S; Williams, RT; Zhang, F; Zhang, J; Zhu, F, 2011)	0.83

Excerpt	Reference	Relevance
" Here, we explored the antitumor potential of cyclin-dependent kinase (CDK) inhibitors in combination with a small molecule inhibitor of p53-murine double minute 2 (MDM2) interaction."	( Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Cheok, CF; Dey, A; Lane, DP, 2007)	0.34
" We examined the effects of the MDM2 inhibitor nutlin3a and its combination with the dual Bcl-2 and Bcl-xL inhibitor ABT-737, and the Bcr-Abl inhibitor nilotinib on BC CML patient samples."	( Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Andreeff, M; Carter, BZ; Champlin, RE; Cortes, J; Kantarjian, HM; Konopleva, M; Mak, DH; Mak, PY; McQueen, T; Ruvolo, VR; Schober, W, 2015)	0.42
"Various cytotoxic agents were evaluated in combination with (131) I-MIP-1095 for their capacity to delay the growth of LNCaP cells cultured as multicellular tumour spheroids."	( Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M, 2016)	0.43
" Nutlin-3 combined with MG-132 narrowed this between-group difference and triggered stronger inhibitory effects on the growth of schwannomas through coordinated reactivation of p53."	( Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. Chen, H; Huang, H; Wang, H; Wang, Z; Wu, H; Xue, L; Zhang, X; Zhu, W, 2018)	0.48
" Here we used nutlin-3 in combination with another potent anticancer drug, doxorubicin, to investigate the synergism between these drugs."	( MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation. Bilir, C; Filipczak, N; Liu, J; Porter, TM; Sarisozen, C; Shen, L; Tan, Y; Torchilin, VP, )	0.13

Excerpt	Reference	Relevance
" Compound 5 has a good oral bioavailability and effectively inhibits tumor growth in the SJSA-1 xenograft model."	( Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. Chen, J; Ding, K; Kang, S; McEachern, D; Miller, R; Nikolovska-Coleska, Z; Qin, D; Qiu, S; Shangary, S; Wang, G; Wang, S; Yang, D; Yu, S, 2009)	0.35
" To overcome the poor bioavailability of Nutlin-3, we have assessed the potential efficacy of Nutlin-3 loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NP) against hematological malignancies."	( Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells. Caruso, L; Forni, F; Palomba, M; Ruozi, B; Secchiero, P; Vandelli, MA; Voltan, R; Zauli, G, 2013)	0.39
" The AURKA/MDM2 combination therapy shows adequate bioavailability and low toxicity to the host."	( Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Ayers, GD; Davis, TA; Ecsedy, JA; Essaka, DC; Hawkins, OE; Horton, LW; Johnston, JN; Kelley, MC; Liu, Y; McClain, CM; Pawlikowski, JS; Richmond, A; Smith, J; Sosman, JA; Stewart, CF; Turner, DC; Vilgelm, AE; Weller, KP, 2015)	0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The final model was used to perform simulations of unbound tissue concentrations to determine which dosing regimens are appropriate for preclinical models of several pediatric malignancies."	( Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Boulos, N; Dyer, MA; Guy, RK; Lu, M; Mallari, J; Miller, L; Nemeth, K; Panetta, JC; Roussel, MF; Stewart, CF; Tagen, M; Throm, S; Williams, RT; Zhang, F; Zhang, J; Zhu, F, 2011)	0.61
" A 4-day dosing schedule in vivo generated a similar response in colon tumors; growth arrest without significantly increased apoptosis."	( Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Belinsky, GS; Giardina, C; Rigatti, MJ; Rosenberg, DW; Verma, R, 2012)	0.38
"7-fold over vehicle) upon oral dosing of 27 at 300 mg/kg."	( Rational design and binding mode duality of MDM2-p53 inhibitors. Bartberger, MD; Beck, HP; Canon, J; Chen, A; Chow, D; Correll, TL; Gonzalez-Lopez de Turiso, F; Huang, X; Julian, LD; Kayser, F; Lo, MC; Long, AM; McMinn, D; Medina, JC; Oliner, JD; Olson, SH; Osgood, T; Powers, JP; Rew, Y; Saiki, AY; Schneider, S; Shaffer, P; Sun, D; Xiao, SH; Yakowec, P; Yan, X; Ye, Q; Yu, D; Zhao, X; Zhou, J, 2013)	0.39
" Using an intermittent dosing schedule of combined carboplatin and Nutlin-3a, there was a significant reduction in primary tumor growth and lung metastases compared with vehicle and single-agent treatments."	( Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Bailey, BJ; Batuello, CN; Ding, J; Eischen, CM; Georgiadis, TM; Gunter, TZ; Hanenberg, H; Long, EC; Marchal, CC; Mayo, LD; Minto, RE; Peterman, KM; Pollok, KE; Saadatzadeh, MR; Safa, AR; Sandusky, GE; Shannon, HE; Silver, JM; Sinn, AL; Spragins, TK; Sprouse, AA; Territo, PR; Tonsing-Carter, E; Wang, H, 2015)	0.89
" This fact has come to notice when a novel method for the drug dosage design is introduced using system oriented concepts."	( On p53 revival using system oriented drug dosage design. Azam, R; Azam, S; Bhatti, AI; Fazal, S; Haseeb, M; Ullah, M, 2017)	0.46
"DNA sequencing and dosage analysis were used to identify the NF2 mutation status in sporadic schwannomas."	( Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. Chen, H; Huang, H; Wang, H; Wang, Z; Wu, H; Xue, L; Zhang, X; Zhu, W, 2018)	0.48
" A comparative analysis is also tabulated with different dosing regimens which shows that a combination of nutlin-3a and a low dose of aspirin provides better results than a high dose of aspirin."	( Effect of pharmacodynamical interaction between nutlin-3a and aspirin in the activation of p53. Aslam, M; Awan, MS; Bhatti, AI; Liaquat, A; Liaquat, M, 2021)	1.09
" Azithromycin and doxycycline demonstrated MICs and MBCs equal or below their peak serum concentrations (PSC) after standard dosing in both cell types."	( Clearing Chlamydia abortus infection in epithelial cells and primary human macrophages by use of antibiotics and the MDM2-p53-inhibitor nutlin-3. Diensthuber, D; Essig, A; Hagemann, JB; Peters, S; Simnacher, U; Walther, P, 2022)	0.72

Class	Description
stilbenoid	Any olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.3379	0.0123	7.9835	43.2770	AID1645841
cytochrome P450 2D6	Homo sapiens (human)	Potency	13.4504	0.0010	8.3798	61.1304	AID1645840
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.3000	0.0023	19.5956	74.0614	AID243263
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	Potency	0.3000	0.3000	0.3000	0.3000	AID243263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Protein Mdm4	Homo sapiens (human)	IC50 (µMol)	4.6273	0.0093	3.7849	8.2000	AID1238675; AID1285801; AID1908071; AID453615
Protein Mdm4	Homo sapiens (human)	Ki	5.8600	5.8600	5.8600	5.8600	AID707317
Cellular tumor antigen p53	Homo sapiens (human)	IC50 (µMol)	3.4349	0.0006	0.8850	8.2000	AID1238620; AID1239847; AID1285800; AID1285801; AID1285802; AID1285803; AID1300245; AID1387289; AID1632470; AID1720556; AID1872997; AID1908070; AID1908071; AID438431; AID438435; AID658338; AID706601; AID706602; AID706603; AID721248
Cellular tumor antigen p53	Homo sapiens (human)	Ki	1.2860	0.0030	1.0736	5.8600	AID626520; AID707317; AID707326; AID749326; AID749491
Apoptosis regulator Bcl-2	Homo sapiens (human)	Ki	10.0000	0.0000	0.1901	2.9000	AID1296598
E3 ubiquitin-protein ligase Mdm2	Mus musculus (house mouse)	Ki	0.0199	0.0199	0.0429	0.0659	AID1238646
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	0.0700	0.0000	2.3983	10.0000	AID1300245
Death-associated protein kinase 1	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0005	2.2845	10.0000	AID1285802
E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)	Ki	0.0105	0.0105	0.0155	0.0205	AID1238645
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	IC50 (µMol)	1.4548	0.0006	0.3582	10.0000	AID1125680; AID1195730; AID1238620; AID1239847; AID1252240; AID1285800; AID1300245; AID1387289; AID1420852; AID1421138; AID1555409; AID1632470; AID1656006; AID1659344; AID1720556; AID1872997; AID1908070; AID265956; AID318566; AID417066; AID453614; AID587349; AID587948; AID658338; AID691697; AID700922; AID706601; AID706602; AID721248; AID738689; AID739072; AID739073; AID746383; AID748501
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	Ki	0.0860	0.0009	0.1981	1.2400	AID1143657; AID1152866; AID1238644; AID1296599; AID1361628; AID1415891; AID1656007; AID1908077; AID265955; AID267242; AID626520; AID684825; AID707326; AID749326; AID749491
Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)	Ki	10.0000	0.0010	1.4653	9.5400	AID1296597
Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0036	0.0036	0.0036	AID1285803
Histone deacetylase 1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	0.5543	9.9000	AID1361627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Apoptosis regulator Bcl-2	Homo sapiens (human)	Kd	15.0000	0.0006	0.9587	4.8000	AID1296639
Delta-type opioid receptor	Mus musculus (house mouse)	Kd	0.5000	0.0002	0.0887	0.5000	AID362382
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	Kd	0.6050	0.0000	0.2585	1.0000	AID1296640; AID362378; AID362381; AID362382; AID362383; AID362384; AID362385
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	Kd	0.5000	0.5000	0.5000	0.5000	AID362385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
heart valve development	Protein Mdm4	Homo sapiens (human)
atrioventricular valve morphogenesis	Protein Mdm4	Homo sapiens (human)
endocardial cushion morphogenesis	Protein Mdm4	Homo sapiens (human)
ventricular septum development	Protein Mdm4	Homo sapiens (human)
atrial septum development	Protein Mdm4	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Protein Mdm4	Homo sapiens (human)
negative regulation of cell population proliferation	Protein Mdm4	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Protein Mdm4	Homo sapiens (human)
negative regulation of protein catabolic process	Protein Mdm4	Homo sapiens (human)
negative regulation of apoptotic process	Protein Mdm4	Homo sapiens (human)
negative regulation of DNA-templated transcription	Protein Mdm4	Homo sapiens (human)
protein stabilization	Protein Mdm4	Homo sapiens (human)
regulation of cell cycle	Protein Mdm4	Homo sapiens (human)
protein-containing complex assembly	Protein Mdm4	Homo sapiens (human)
cellular response to hypoxia	Protein Mdm4	Homo sapiens (human)
protein ubiquitination	Protein Mdm4	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
protein polyubiquitination	Apoptosis regulator Bcl-2	Homo sapiens (human)
apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to xenobiotic stimulus	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to toxic substance	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of cell growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to cytokine	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of calcium ion transport	Apoptosis regulator Bcl-2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Apoptosis regulator Bcl-2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Apoptosis regulator Bcl-2	Homo sapiens (human)
ossification	Apoptosis regulator Bcl-2	Homo sapiens (human)
ovarian follicle development	Apoptosis regulator Bcl-2	Homo sapiens (human)
metanephros development	Apoptosis regulator Bcl-2	Homo sapiens (human)
branching involved in ureteric bud morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
behavioral fear response	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell homeostasis	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
release of cytochrome c from mitochondria	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of cell-matrix adhesion	Apoptosis regulator Bcl-2	Homo sapiens (human)
lymphoid progenitor cell differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell lineage commitment	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of B cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to ischemia	Apoptosis regulator Bcl-2	Homo sapiens (human)
renal system process	Apoptosis regulator Bcl-2	Homo sapiens (human)
melanin metabolic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of nitrogen utilization	Apoptosis regulator Bcl-2	Homo sapiens (human)
autophagy	Apoptosis regulator Bcl-2	Homo sapiens (human)
humoral immune response	Apoptosis regulator Bcl-2	Homo sapiens (human)
DNA damage response	Apoptosis regulator Bcl-2	Homo sapiens (human)
actin filament organization	Apoptosis regulator Bcl-2	Homo sapiens (human)
axonogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
female pregnancy	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of cell population proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
male gonad development	Apoptosis regulator Bcl-2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to radiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to xenobiotic stimulus	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to toxic substance	Apoptosis regulator Bcl-2	Homo sapiens (human)
post-embryonic development	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to iron ion	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to UV-B	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to gamma radiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of gene expression	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of autophagy	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of calcium ion transport into cytosol	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of glycoprotein biosynthetic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
mesenchymal cell development	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of neuron maturation	Apoptosis regulator Bcl-2	Homo sapiens (human)
smooth muscle cell migration	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Apoptosis regulator Bcl-2	Homo sapiens (human)
cochlear nucleus development	Apoptosis regulator Bcl-2	Homo sapiens (human)
gland morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of transmembrane transporter activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of ossification	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of cell growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
melanocyte differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of cell migration	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of B cell proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
hair follicle morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
axon regeneration	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of protein stability	Apoptosis regulator Bcl-2	Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasis	Apoptosis regulator Bcl-2	Homo sapiens (human)
glomerulus development	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of cellular pH reduction	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of protein localization	Apoptosis regulator Bcl-2	Homo sapiens (human)
myeloid cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of myeloid cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
T cell differentiation in thymus	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Apoptosis regulator Bcl-2	Homo sapiens (human)
osteoblast proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of osteoblast proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to nicotine	Apoptosis regulator Bcl-2	Homo sapiens (human)
organ growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of multicellular organism growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
cellular response to glucose starvation	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to hydrogen peroxide	Apoptosis regulator Bcl-2	Homo sapiens (human)
neuron maturation	Apoptosis regulator Bcl-2	Homo sapiens (human)
T cell homeostasis	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
CD8-positive, alpha-beta T cell lineage commitment	Apoptosis regulator Bcl-2	Homo sapiens (human)
ear development	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of viral genome replication	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of melanocyte differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
retinal cell programmed cell death	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of retinal cell programmed cell death	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Apoptosis regulator Bcl-2	Homo sapiens (human)
focal adhesion assembly	Apoptosis regulator Bcl-2	Homo sapiens (human)
spleen development	Apoptosis regulator Bcl-2	Homo sapiens (human)
thymus development	Apoptosis regulator Bcl-2	Homo sapiens (human)
digestive tract morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
oocyte development	Apoptosis regulator Bcl-2	Homo sapiens (human)
skeletal muscle fiber development	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of skeletal muscle fiber development	Apoptosis regulator Bcl-2	Homo sapiens (human)
pigment granule organization	Apoptosis regulator Bcl-2	Homo sapiens (human)
stem cell development	Apoptosis regulator Bcl-2	Homo sapiens (human)
homeostasis of number of cells within a tissue	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell receptor signaling pathway	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to glucocorticoid	Apoptosis regulator Bcl-2	Homo sapiens (human)
neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
defense response to virus	Apoptosis regulator Bcl-2	Homo sapiens (human)
establishment of localization in cell	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of mitochondrial membrane potential	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Apoptosis regulator Bcl-2	Homo sapiens (human)
hematopoietic stem cell differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
calcium ion transport into cytosol	Apoptosis regulator Bcl-2	Homo sapiens (human)
T cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of T cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
cellular response to organic substance	Apoptosis regulator Bcl-2	Homo sapiens (human)
cellular response to hypoxia	Apoptosis regulator Bcl-2	Homo sapiens (human)
reactive oxygen species metabolic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
dendritic cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
motor neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
cell-cell adhesion	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Apoptosis regulator Bcl-2	Homo sapiens (human)
epithelial cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of epithelial cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycle	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of dendritic cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of motor neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of anoikis	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Apoptosis regulator Bcl-2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Apoptosis regulator Bcl-2	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Apoptosis regulator Bcl-2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
apoptotic process	Death-associated protein kinase 1	Homo sapiens (human)
defense response to tumor cell	Death-associated protein kinase 1	Homo sapiens (human)
regulation of response to tumor cell	Death-associated protein kinase 1	Homo sapiens (human)
protein phosphorylation	Death-associated protein kinase 1	Homo sapiens (human)
apoptotic process	Death-associated protein kinase 1	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Death-associated protein kinase 1	Homo sapiens (human)
regulation of autophagy	Death-associated protein kinase 1	Homo sapiens (human)
positive regulation of autophagy	Death-associated protein kinase 1	Homo sapiens (human)
negative regulation of translation	Death-associated protein kinase 1	Homo sapiens (human)
intracellular signal transduction	Death-associated protein kinase 1	Homo sapiens (human)
regulation of apoptotic process	Death-associated protein kinase 1	Homo sapiens (human)
positive regulation of apoptotic process	Death-associated protein kinase 1	Homo sapiens (human)
negative regulation of apoptotic process	Death-associated protein kinase 1	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Death-associated protein kinase 1	Homo sapiens (human)
protein autophosphorylation	Death-associated protein kinase 1	Homo sapiens (human)
cellular response to type II interferon	Death-associated protein kinase 1	Homo sapiens (human)
cellular response to hydroperoxide	Death-associated protein kinase 1	Homo sapiens (human)
apoptotic signaling pathway	Death-associated protein kinase 1	Homo sapiens (human)
positive regulation of autophagic cell death	Death-associated protein kinase 1	Homo sapiens (human)
regulation of NMDA receptor activity	Death-associated protein kinase 1	Homo sapiens (human)
apoptotic process	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
protein ubiquitination	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
regulation of cell cycle	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
regulation of biological quality	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
regulation of cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein polyubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
blood vessel development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
blood vessel remodeling	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of heart rate	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
atrioventricular valve morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocardial cushion morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ventricular septum development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
atrial septum development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
apoptotic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
traversing start control point of mitotic cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of cell population proliferation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to xenobiotic stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to toxic substance	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to iron ion	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of gene expression	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of protein processing	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of neuron projection development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein ubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein sumoylation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein destabilization	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to magnesium ion	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein localization to nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to cocaine	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
establishment of protein localization	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to ether	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of DNA-templated transcription	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of mitotic cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to antibiotic	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of protein export from nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to steroid hormone	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of muscle cell differentiation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
proteolysis involved in protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein autoubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cardiac septum morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex assembly	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to hydrogen peroxide	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to vitamin B1	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to alkaloid	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to growth factor stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to peptide hormone stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to estrogen stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to hypoxia	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to gamma radiation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to UV-C	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
fibroblast activation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to actinomycin D	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of signal transduction by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to formaldehyde	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migration	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
amyloid fibril formation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to water-immersion restraint stress	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of apoptotic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of gene expression	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
DNA damage response	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
response to cytokine	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cell fate determination	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of autophagy	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cellular homeostasis	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
positive regulation of apoptotic process	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of apoptotic process	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
protein transmembrane transport	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of anoikis	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrial fusion	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
release of cytochrome c from mitochondria	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
apoptotic process	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein transport	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
viral release from host cell	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
lipid droplet organization	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
positive regulation of apoptotic process	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
positive regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
positive regulation of protein secretion	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein-containing complex assembly	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cellular response to UV-A	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
chromatin organization	Histone deacetylase 1	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
protein deacetylation	Histone deacetylase 1	Homo sapiens (human)
endoderm development	Histone deacetylase 1	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 1	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
hippocampus development	Histone deacetylase 1	Homo sapiens (human)
neuron differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Histone deacetylase 1	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 1	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 1	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Histone deacetylase 1	Homo sapiens (human)
negative regulation by host of viral transcription	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Histone deacetylase 1	Homo sapiens (human)
oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 1	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 1	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Histone deacetylase 1	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Histone deacetylase 1	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Protein Mdm4	Homo sapiens (human)
zinc ion binding	Protein Mdm4	Homo sapiens (human)
enzyme binding	Protein Mdm4	Homo sapiens (human)
ubiquitin-protein transferase activity	Protein Mdm4	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
channel activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
channel inhibitor activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
ubiquitin protein ligase binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
identical protein binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
sequence-specific DNA binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein heterodimerization activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
BH3 domain binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein phosphatase 2A binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
molecular adaptor activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
DNA-binding transcription factor binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
BH domain binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
protein kinase activity	Death-associated protein kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Death-associated protein kinase 1	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Death-associated protein kinase 1	Homo sapiens (human)
protein binding	Death-associated protein kinase 1	Homo sapiens (human)
calmodulin binding	Death-associated protein kinase 1	Homo sapiens (human)
ATP binding	Death-associated protein kinase 1	Homo sapiens (human)
GTP binding	Death-associated protein kinase 1	Homo sapiens (human)
syntaxin-1 binding	Death-associated protein kinase 1	Homo sapiens (human)
identical protein binding	Death-associated protein kinase 1	Homo sapiens (human)
protein serine kinase activity	Death-associated protein kinase 1	Homo sapiens (human)
5S rRNA binding	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
identical protein binding	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
ribonucleoprotein complex binding	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
ubiquitin binding	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
metal ion binding	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
p53 binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-protein transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
5S rRNA binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
zinc ion binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
SUMO transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
enzyme binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
receptor serine/threonine kinase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
identical protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
peroxisome proliferator activated receptor binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ribonucleoprotein complex binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
NEDD8 ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
disordered domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein binding	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
protein transmembrane transporter activity	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
protein heterodimerization activity	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
BH3 domain binding	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
channel activity	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
BH domain binding	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
transcription factor binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nuclear estrogen receptor binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
Hsp70 protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
heat shock protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
Hsp90 protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 1	Homo sapiens (human)
p53 binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
protein binding	Histone deacetylase 1	Homo sapiens (human)
enzyme binding	Histone deacetylase 1	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
Krueppel-associated box domain binding	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 1	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
E-box binding	Histone deacetylase 1	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 1	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Protein Mdm4	Homo sapiens (human)
nucleoplasm	Protein Mdm4	Homo sapiens (human)
transcription repressor complex	Protein Mdm4	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial outer membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
endoplasmic reticulum membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
nucleus	Apoptosis regulator Bcl-2	Homo sapiens (human)
cytoplasm	Apoptosis regulator Bcl-2	Homo sapiens (human)
mitochondrion	Apoptosis regulator Bcl-2	Homo sapiens (human)
mitochondrial outer membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
endoplasmic reticulum	Apoptosis regulator Bcl-2	Homo sapiens (human)
cytosol	Apoptosis regulator Bcl-2	Homo sapiens (human)
membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
nuclear membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
myelin sheath	Apoptosis regulator Bcl-2	Homo sapiens (human)
BAD-BCL-2 complex	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein-containing complex	Apoptosis regulator Bcl-2	Homo sapiens (human)
pore complex	Apoptosis regulator Bcl-2	Homo sapiens (human)
cytosol	E3 ubiquitin-protein ligase Mdm2	Mus musculus (house mouse)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Death-associated protein kinase 1	Homo sapiens (human)
plasma membrane	Death-associated protein kinase 1	Homo sapiens (human)
postsynaptic density	Death-associated protein kinase 1	Homo sapiens (human)
actin cytoskeleton	Death-associated protein kinase 1	Homo sapiens (human)
glutamatergic synapse	Death-associated protein kinase 1	Homo sapiens (human)
DAPK1-calmodulin complex	Death-associated protein kinase 1	Homo sapiens (human)
cytoplasm	Death-associated protein kinase 1	Homo sapiens (human)
nucleus	Death-associated protein kinase 1	Homo sapiens (human)
nucleus	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
nucleoplasm	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
nucleolus	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
cytoplasm	E3 ubiquitin-protein ligase Mdm2	Canis lupus familiaris (dog)
nuclear body	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleolus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytosol	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
plasma membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
transcription repressor complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocytic vesicle membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleus	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
nucleoplasm	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cytoplasm	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrion	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrial outer membrane	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cytosol	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
membrane	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
Bcl-2 family protein complex	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrial outer membrane	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nucleolus	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Homo sapiens (human)
cytoplasm	Histone deacetylase 1	Homo sapiens (human)
cytosol	Histone deacetylase 1	Homo sapiens (human)
NuRD complex	Histone deacetylase 1	Homo sapiens (human)
neuronal cell body	Histone deacetylase 1	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 1	Homo sapiens (human)
chromatin	Histone deacetylase 1	Homo sapiens (human)
heterochromatin	Histone deacetylase 1	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 1	Homo sapiens (human)
protein-containing complex	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (378)

Assay ID	Title	Year	Journal	Article
AID756930	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 3 uM after 24 to 72 hrs by annexin V-FITC/propidium iodide staining based FACS flow cytometry (Rvb = 4 %)	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1125680	Binding affinity to HDM2 (unknown origin) by fluorescence polarization peptide displacement assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
AID1908076	Displacement of 5-FAM labeled PDI peptide from MDM4 C17S mutant (14 to 111 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant incubated for 1.5 hrs by fluorescence polarization competition assay
AID756946	Cytotoxicity against human HGF cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID748499	Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID706602	Inhibition of human MDM2-p53 interaction after 18 hrs by HTRF assay in presence of 15% human serum	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-based design of novel inhibitors of the MDM2-p53 interaction.
AID1238620	Inhibition of MDM2/p53 interaction (unknown origin) using biotinylated MDM2 and Cy5-p53 (18 to 26 amino acids) by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1285810	Upregulation of p53 in human MCF7 cells after 24 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID621852	Growth inhibition of p53 deficient human HCT116 cells expressing MDM2 by SRB assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
AID1125677	Permeability of the compound in human Caco2 cells	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
AID1908032	Upregulation of p53 protein expression in human NCI-H460 cells at 10 uM measured after 24 hrs by Western blot analysis
AID1300940	Decrease in procaspase-3 expression level in human p53-null HCT116 -/- cells at 10 uM after 24 hrs by western blot analysis	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID739072	Inhibition of human recombinant GST-thrombin-MDM2 (1 to 188) expressed in Escherichia coli assessed as reduction of MDM2-p53 interaction incubated for 20 mins followed by p53 addition measured after 60 mins by HTRF assay in presence of 15% serum	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Rational design and binding mode duality of MDM2-p53 inhibitors.
AID541422	Inhibition of human recombinant p53-MDM2 interaction assessed as p53 release by NMR spectroscopy relative to untreated control	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators.
AID1296620	Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at G1 phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 28%)	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID626520	Inhibition of Mdm2-p53 protein interaction preincubated for 30 mins by fluorescence polarization assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
AID756944	Inhibition of p53-MDM2 interaction (unknown origin) at 5 uM after 1 hr by ELISA	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1212290	Drug uptake in C57BL/6 mouse plasma at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1366819	Growth inhibition of human HCT116 cells harboring p53+/+ after 48 hrs by Hoechst 33258 staining based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID503026	Antiproliferative activity against human MCF7 cells at 4 uM after 14 days by coomassie staining	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1908081	Cytotoxicity against human U2OS cells expressing wild type p53 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID1155057	Antiproliferative activity against human SK-UT-1 cells expressing p53 mutant protein by cell Titer-Glo assay	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
AID756938	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 3 uM after 24 to 72 hrs by propidium iodide staining-based FACS analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1361647	Induction of apoptosis in human A549 cells assessed as viable cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 93.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID503032	Induction of cell cycle arrest in human MCF7 cells 53BP1-targeting iRNA-based shRNA assessed as accumulation at S phase at 4 uM after 48 hrs by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID749326	Inhibition of p53-MDM2 (unknown origin) interaction expressed in Escherichia coli BL-21 (DE3) after 1 hr by fluorescence polarization assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
AID1296639	Binding affinity to 15N-labeled Bcl-2 (unknown origin) by 2D 1H-15N HSQC NMR spectroscopic method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1143658	Antiproliferative activity against human HCT116 cells expressing wild type p53 after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID738689	Inhibition of MDM2 (unknown origin) assessed as activation of p53	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID415699	Inhibition of interaction between human DMX(1-555) and p53 at upto 30 uM	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Beta-peptides with improved affinity for hDM2 and hDMX.
AID1296597	Displacement of FAM-Bid peptide from N-terminal 8x His-tagged MCl-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) after 30 mins by fluorescence polarization assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1908031	Upregulation of MDM2 protein expression in human NCI-H460 cells at 10 uM measured after 24 hrs by Western blot analysis
AID739073	Inhibition of human recombinant GST-thrombin-MDM2 (1 to 188) expressed in Escherichia coli assessed as reduction of MDM2-p53 interaction incubated for 20 mins followed by p53 addition measured after 60 mins by HTRF assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Rational design and binding mode duality of MDM2-p53 inhibitors.
AID1212300	Drug uptake in C57BL/6 mouse liver at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID362381	Binding affinity to human recombinant Mdm2 T101W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	NMR screening for lead compounds using tryptophan-mutated proteins.
AID707326	Inhibition of p53-MDM2 interaction after 1 hr by fluorescence polarization assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID265955	Displacement of PMDM6-F from human recombinant MDM2	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
AID438432	Induction of p21 mRNA in human HCT116 cells by RT-PCR	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID738714	Antiproliferative activity against human RKO cells expressing wild type p53 after 5 days by MTS assay	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID587349	Inhibition of human GST-tagged Mdm2 expressed in Escherichia coli harboring integrated p53-Mmd2 protein assessed as blockade of enzyme-p53 interaction by ELISA assay	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.
AID1300910	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID1361650	Induction of apoptosis in human A549 cells assessed as necrotic cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 0.52%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1249875	Activation of p53 in human U2OS cells assessed as increase of MDM2 expression at 2.5 uM after 12 hrs by Western blotting	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Discovery of Novel Isatin-Based p53 Inducers.
AID1212292	Drug uptake in C57BL/6 mouse adrenal gland at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID749490	Cytotoxicity against human p53 deficient PC3 cells after 72 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
AID621851	Growth inhibition of human HCT116 cells expressing MDM2 by SRB assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
AID1674908	Inhibition of P-gp-mediated Rhodamine-123 efflux in human p53 +/+ H1299 cells assessed as Rhodamine-123 accumulation measured after 40 mins by spectrofluorimetry	2020	Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18	Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors.
AID362385	Binding affinity to human recombinant Mdm2 F55W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	NMR screening for lead compounds using tryptophan-mutated proteins.
AID1908078	Cytotoxicity against human RKO cells expressing wild type p53 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID1361624	Growth inhibition of Saccharomyces cerevisiae expressing p53 at 10 uM after 42 hrs by Yeast-based assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
AID749488	Inhibition of p53/MDM2 (1 to 118) (unknown origin) interaction at 10 uM after 1 hr by fluorescence polarization assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
AID1285800	Inhibition of Flag-tagged p53/GST-tagged Mdm2 (unknown origin) expressed in Escherichia coli BL21 after 1 hr by ELISA microplate reader method	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID1300908	Antiproliferative activity against human HCT116 cells expressing wild type p53 assessed as growth inhibition after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID1361627	Inhibition of human recombinant full length HDAC1 using fluorogenic substrate 3 after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1361653	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.37%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1195733	Cytotoxicity against human RKO cells	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
AID749491	Inhibition of p53/MDM2 (1 to 118) (unknown origin) interaction after 1 hr by fluorescence polarization assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
AID503037	Induction of p53 accumulation in human MCF7 cells after 18 hrs by Western blot analysis in presence of 2.5 mM caffeine	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1296633	Inhibition of BCl-2/Bax interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID749324	Cytotoxicity against human p53-null PC3 cells assessed as growth inhibition after 72 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
AID1361625	Growth inhibition of Saccharomyces cerevisiae expressing MDM2 at 10 uM after 42 hrs by Yeast-based assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
AID1285803	Inhibition of Flag-tagged p53/GST-tagged PPID (unknown origin) expressed in Escherichia coli BL21 after 1 hr by ELISA microplate reader method	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID756857	Inhibition of MDM2-P53 interaction in human SJSA1 cells assessed as p53-mediated decrease in full length PARP level at 24 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
AID1212304	Drug uptake in C57BL/6 mouse lung at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1659344	Inhibition of MDM2 (unknown origin) by HTRF assay	2020	Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15	Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
AID1296640	Binding affinity to 15N-labeled MDM2 (unknown origin) by 2D 1H-15N HSQC NMR spectroscopic method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID736743	Inhibition of human p53 expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell cycle arrest at 10 uM after 42 hrs	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1285816	Antitumor activity against human HCT116 cells xenografted in nude BALB/c mouse assessed as decrease in tumor growth at 150 mg/kg/day, po administered every other day until day 38 and measured on day 40	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID1720556	Inhibition of human MDM2-p53 interaction	2020	Bioorganic & medicinal chemistry, 07-01, Volume: 28, Issue:13	A critical update on the strategies towards modulators targeting androgen receptors.
AID1908070	Inhibition of GST-tagged MDM2/Biotin-tagged p53 interaction (unknown origin) incubated for 40 mins by TR-FRET assay
AID1060451	Antiproliferative activity against human HepG2 cells after 24 hrs by MTS assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents.
AID1155058	Ratio of IC50 for human SK-UT-1 cells expressing p53 mutant protein to IC50 for human SJSA1 cells expressing wild type p53 protein	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
AID1057111	Cytotoxicity against human HCT116 cells after 72 hrs by CellTiterGlo luciferase-based assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.
AID503033	Induction of p53 expression in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA by Western blot analysis	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1296632	Inhibition of BCl-2/Bim interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1143671	Induction of apoptosis in human HCT116 cells assessed as accumulation at G2 phase at 20 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1361637	Inhibition of MDM2/P53 interaction in human A549 cells assessed as increase in MDM2 expression after 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID691697	Inhibition of MDM2 binding to p53	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
AID1632470	Inhibition of C-terminal biotin-tagged streptavidin labelled human MDM2 ( 2 to 188 residues)/Cy5-labelled p53 (18 to 26 residues)(unknown origin) interaction after 15 mins by TR-FRET assay	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
AID1387292	Antiproliferative activity against p53 -/- human HCT116 cells incubated for 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
AID588009	Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of MDM2 protein at 1 to 10 uM after 6 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID1296626	Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 35%)	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID756926	Induction of apoptosis in human MCF7 cells assessed as increase in p21 expression level at 3 uM after 24 to 72 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1361648	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.10%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1361626	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1212302	Drug uptake in C57BL/6 mouse plasma at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1238647	Inhibition of rat MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1361643	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2 phase at 1 uM after 48 hrs by flow cytometric analysis (Rvb = 19.81%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID748501	Inhibition of N-terminal human recombinant MDM2 assessed as inhibition of protein interaction with p53 by HTRF assay	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID738727	Antiproliferative activity against human MDA-MB-435S cells harboring p53 mutant at 10 uM after 5 days by MTS assay	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID1060449	Antiproliferative activity against p53-deficient human HCT116 cells after 24 hrs by MTS assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents.
AID1296634	Inhibition of Mcl-1/Bim interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID748504	Apparent half life in mouse at 100 mg/kg, po	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID1212283	Ratio of drug level in blood to plasma in C57BL/6 mouse after 30 mins	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1238675	Inhibition of human MDM4 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID503024	Induction of cell cycle arrest in human MCF7 cells transfected with p53-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID442457	Inhibition of MDM2-p53 interaction in human SJSA1 cells assessed as p53 activation at 10 uM by Western blot	2009	Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24	Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
AID621853	Growth inhibition of human A2780 cells expressing MDM2 by SRB assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
AID1392508	Cytotoxicity against human U2OS cells harboring p53-dependent EGFP reporter gene assessed as reduction in cell viability at 30 uM after 48 hrs	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction.
AID503034	Induction of p53 expression in human MCF7 cells by Western blot analysis	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID425673	Inhibition of GST-tagged MDM2 (1-150) / full-length His6-tagged p53 interaction expressed in Escherichia coli by alphascreen assay	2009	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14	Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking.
AID1361646	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2 phase at 5 uM after 48 hrs by flow cytometric analysis (Rvb = 19.81%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID756948	Cytotoxicity against human Calu cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID626522	Antitumor activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
AID1908079	Cytotoxicity against human MCF7 cells expressing wild type p53 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID1656003	Solubility of compound in PBS	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR.
AID707325	Antiproliferative activity against p53 deficient human Saos2 cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID1361631	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1212285	Fraction unbound in C57BL/6 mouse plasma at 300 uM up to 24 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1285814	Increase in p53 expression in human MCF7 cells nuclei after 24 hrs by DAPI staining based immunofluorescence microscopy	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID1908093	Induction of PARP cleavage in human RKO cells at 0.3125 to 2.5 uM incubated for 24 hrs by Western blot analysis
AID1361644	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G1 phase at 5 uM after 48 hrs by flow cytometric analysis (Rvb = 49.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1143670	Induction of apoptosis in human HCT116 cells assessed as accumulation at S phase at 20 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1908055	Upregulation of p53 protein expression in human U2OS cells at 10 uM measured after 24 hrs by Western blot analysis
AID1565005	Induction of apoptosis in human HCT116 cells expressing wild type p53 assessed as live cells at 20 uM measured after 72 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry analysis (Rvb = 83.7 %)	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID1908092	Downregulation of MDM4 expression in human RKO cells at 0.3125 to 2.5 uM incubated for 24 hrs by Western blot analysis
AID1060450	Antiproliferative activity against human HCT116 cells expressing p53 after 24 hrs by MTS assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents.
AID588013	Cytotoxicity against human SJSA1 cells after 72 hrs by sulforhodamine B assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID587948	Inhibition of Mdm2 -p53 protein interaction by ELISA	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID1212294	Drug uptake in C57BL/6 mouse muscle at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1296607	Inhibition of MDM2-p53 interaction in human HCT116 p53+/+ cells assessed as upregulation of p53 expression after 12 hrs by immunoblotting method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID438434	Induction of apoptosis in human SJSA1 cells assessed as caspase 3/7 activity after 48 hrs	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID746383	Antagonist activity at human GST-tagged MDM2 assessed as inhibition of binding to full length p53	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
AID1125681	Antiproliferative activity against human SJSA1 cells	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
AID1212296	Drug uptake in C57BL/6 mouse brain at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1143669	Induction of apoptosis in human HCT116 cells assessed as accumulation at G1 phase at 20 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID588016	Cytotoxicity against human p53 expressing HCT116 cells after 72 hrs by sulforhodamine B assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID1908058	Cytotoxicity against human HCT-116 cells expressing wild type p53 and MDM2 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID1239847	Inhibition of p53-MDM2 interaction (unknown origin) by TR-FRET assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
AID1285811	Upregulation of p21 in human MCF7 cells after 24 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID453614	Binding to HDM2 expressed in Escherichia coli BL21 (DE3) by fluorescence anisotropy competition method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
AID1908028	Upregulation of p53 protein expression in human MCF7 cells at 10 uM measured after 24 hrs by Western blot analysis
AID1565006	Induction of apoptosis in human HCT116 cells expressing wild type p53 assessed as early apoptotic cells expressing wild type p53 at 20 uM measured after 72 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry analysis (Rvb = 8.8 %)	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID1296623	Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at S phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 42%)	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1296624	Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 31%)	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1057102	Ratio of IC50 for human H1299 cells to IC50 for human HCT116 cells	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.
AID707311	Induction of apoptosis in human A549 cells expressing wild type p53 at 20 uM after 48 hrs using annexin V-FITC staining by flow cytometry assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID1908077	Displacement of 5-FAM labeled PDI peptide from MDM2 (1 to 118 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant incubated for 1.5 hrs by fluorescence polarization competition assay
AID700922	Inhibition of HDM2 binding to p53	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	Chemical modulators working at pharmacological interface of target proteins.
AID503039	Induction of apoptosis in human MCF7 cells transfected with p53-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1361641	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G1 phase at 1 uM after 48 hrs by flow cytometric analysis (Rvb = 49.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID438435	Induction of p53-Ser15 phosphorylation in human HCT116 cells after 24 hrs	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID1060441	Inhibition of p53-MDM2 (unknown origin) interaction expressed in p53-deficient human HCT116 cells at 50 uM after 24 hrs by BiFC-based FACS flow cytometric analysis	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents.
AID1143674	Induction of apoptosis in human HCT116 cells assessed as accumulation at G2 phase at 50 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.7%)	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1361623	Growth inhibition of Saccharomyces cerevisiae expressing empty vector at 10 uM after 42 hrs by Yeast-based assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
AID1192743	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID1060447	Antiproliferative activity against human SW620 cells expressing p53 mutant after 24 hrs by MTS assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents.
AID1212301	Drug uptake in C57BL/6 mouse spleen at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1212297	Drug uptake in C57BL/6 mouse bone marrow at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID621854	Growth inhibition of human A2780/CP70 cells expressing isogenically paired p53 mutant by SRB assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
AID1908053	Upregulation of p21 protein expression in human NCI-H460 cells at 10 uM measured after 24 hrs by Western blot analysis
AID1361654	Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 0.52%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID318566	Binding affinity to human HDM2 assessed as inhibition of HDM2-p53 interaction	2007	Nature, Dec-13, Volume: 450, Issue:7172	Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
AID503025	Induction of cell cycle arrest in human MCF7 cells transfected hnRNPK-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1212295	Drug uptake in C57BL/6 mouse retina at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1908027	Upregulation of p21 protein expression in human MCF7 cells at 10 uM measured after 24 hrs by Western blot analysis
AID1565008	Induction of apoptosis in human HCT116 cells expressing wild type p53 assessed as necrotic cells at 20 uM measured after 72 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry analysis (Rvb = 0.7 %)	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID1238650	Selectivity index, ratio of Ki for rat MDM2 to Ki for human MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1872997	Inhibition of recombinant human MDM2/p53 interaction by Biacore's surface plasmon resonance analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.
AID1296625	Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at S phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 36%)	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1300246	Antiproliferative activity against human SJSA1 cells expressing wild type p53 after 72 hrs by CellTitre-Glo assay	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
AID1656006	Inhibition of 6xHis-taged MDM2 (unknown origin) expressed in Escherichia coli Gold (DE3)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR.
AID1195731	Cytotoxicity against human SJSA1 cells	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
AID1654661	Inhibition of mdm2 in human ARN8 cells assessed as induction of DNA damage by measuring increase in p53 phosphorylation at Ser15 at 2 uM incubated for 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID1633977	Inhibition of MDM2/P53 interaction in human RKO cells assessed as ratio of p53 to GAPDH level at 20 uM after 24 hrs by Western blot analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
AID587354	Induction of p53-dependent luciferase activity in human U2OS cells at 5 uM relative to control	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.
AID1195732	Cytotoxicity against human HCT116 cells	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
AID1143668	Induction of apoptosis in human HCT116 cells assessed as accumulation at G2 phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID362383	Binding affinity to human recombinant Mdm2 K98W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	NMR screening for lead compounds using tryptophan-mutated proteins.
AID1300941	Decrease in procaspase-9 expression level in human p53-null HCT116 -/- cells at 10 uM after 24 hrs by western blot analysis	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID1361628	Inhibition of MDM2 (unknown origin) preincubated for 30 mins by fluorescence polarization assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1212293	Drug uptake in C57BL/6 mouse lung at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1555409	Inhibition of p53 protein binding to MDM2 (unknown origin)	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
AID1420852	Inhibition of recombinant p53 protein binding to recombinant human MDM2 by surface plasmon resonance method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Role of p53 circuitry in tumorigenesis: A brief review.
AID1366814	Inhibition of MDM2/p53 interaction in human U2OS cells assessed as p53 activation by measuring EGFP-positive cells at 10 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopic analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID738716	Antiproliferative activity against human HCT116 cells expressing wild type p53 after 5 days by MTS assay	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID588014	Cytotoxicity against human LS cells after 72 hrs by sulforhodamine B assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID1387289	Inhibition of human MDM2 (1 to 125 residues) and p53 (unknown origin) interaction pre-incubated for 20 mins before peptide-2-biot addition and measured after 3 hrs by HTRF assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
AID1296635	Inhibition of Mcl-1/Bax interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1252240	Inhibition of human MDM2 (17 to 125 residues) assessed as reduction in MDM2 interaction with FAM-LTFEHYWAQLTS-CONH2 peptide incubated for 30 mins by fluorescence polarisation assay	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.
AID1152866	Binding affinity to MDM2 (unknown origin) assessed as inhibition of interaction with p53 after 1 hr by fluorescence polarization binding assay	2014	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12	Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
AID1654653	Inhibition of mdm2 in human ARN8 cells assessed as increase in p53 level at 2 uM incubated for 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID1633983	Inhibition of MDM2/P53 interaction in human A549 cells assessed as ratio of p53 to GAPDH level at 80 uM after 24 hrs by Western blot analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
AID1212284	Fraction unbound in C57BL/6 mouse plasma at 0.1 uM up to 24 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID748498	Cytotoxicity against human RKO cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID1361619	Inhibition of human MDM2-p53 interaction in Saccharomyces cerevisiae assessed as p53 induced cell growth arrest at 10 uM after 42 hrs by Yeast-based assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
AID756940	Inhibition of MDM2-p53 interaction in human MCF7 cells assessed as reduction in p53 level bound to MDM2 after 24 hrs by immunoprecipitation assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1908080	Cytotoxicity against human NCI-H460 cells expressing wild type p53 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID503036	Induction of p53 expression in human MCF7 cells assessed as increase in p21CIP1 level after 18 hrs by Western blot method in presence of 2.5 mM caffeine	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1143657	Binding affinity to MDM2 (1 to 118) (unknown origin) after 30 mins by fluorescence polarization assay	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1366812	Induction of apoptosis in human U2OS cells at 10 uM after 24 hrs by Annexin V-FITC/propidium iodide based FACS analysis (Rvb= 0.1%)	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID756860	Inhibition of MDM2-p53 interaction in human SJSA1 cells assessed as p53 activation after 24 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
AID1212308	Drug uptake in C57BL/6 mouse bone marrow at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1366818	Growth inhibition of human p53 knockdown HCT116 cells after 48 hrs by Hoechst 33258 staining based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID438433	Inhibition of human HCT116 cell proliferation after 16 hrs by BrdU assay	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID756953	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID658338	Inhibition of p53 (18 to 26)-MDM2 (2 to 188) interaction using fluorescent dye Cy5 by TR-FRET assay	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.
AID1372140	Cytotoxicity in human SJSA1 cells over expressing human DM2 after 24 hrs by CellTiter-Glo assay	2018	Bioorganic & medicinal chemistry, 03-15, Volume: 26, Issue:6	Unique arginine array improves cytosolic localization of hydrocarbon-stapled peptides.
AID736737	Inhibition of human MDM2-p53 interaction expressed in Saccharomyces cerevisiae CG379 assessed as reversal of MDM2-dependent inhibition of p53-induced S-phase cell cycle arrest at 10 uM after 42 hrs by Sytox Green-based flow cytometric analysis	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1238649	Selectivity index, ratio of Ki for mouse MDM2 to Ki for human MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID588017	Cytotoxicity against p53 deficient human HCT116 cells after 72 hrs by sulforhodamine B assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID756858	Inhibition of MDM2-p53 interaction in human SJSA1 cells assessed as accumulation of p21 after 24 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
AID1175611	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
AID1654654	Inhibition of mdm2 in human ARN8 cells assessed as increase in p53 level at 2 uM incubated for 24 hrs in presence of 100 uM de novo pyrimidine ribonucleotide synthesis pathway inhibitor, uridine by Western blot analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID503028	Antiproliferative activity against human MCF7 cells transfected with p53-targeting iRNA-based shRNA assessed as effect on cellular morphology at 4 uM after 14 days by coomassie staining	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1564997	Displacement of 5'FAM-LTFEHYWAQLTS from human recombinant N-terminal domain of MDM2 (1 to 118 residues) expressed in Escherichia coli BL21 (DE3) cells measured after 15 mins by fluorescence polarization assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID1192744	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID706604	Antiproliferative activity against human SJSA1 cells after 3 days by EdU incorporation assay in presence of 10% human serum	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-based design of novel inhibitors of the MDM2-p53 interaction.
AID756951	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1908060	Upregulation of p21 protein expression in human U2OS cells at 10 uM measured after 24 hrs by Western blot analysis
AID1285813	Increase in p53 expression in human IMR32 cells nuclei after 24 hrs by DAPI staining based immunofluorescence microscopy	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID1361651	Induction of apoptosis in human A549 cells assessed as viable cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 93.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1565010	Inhibition of MDM2-p53 interaction in human SJSA1 cells expressing wild-type p53 assessed as upregulation of p21 expression at 5 uM measured after 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID453615	Binding to GST-tagged HDMX expressed in Escherichia coli BL21 (DE3) by fluorescence anisotropy competition method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
AID1296609	Inhibition of MDM2-p53 interaction in human HCT116 p53+/+ cells assessed as upregulation of MDM2 expression after 12 hrs by immunoblotting method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1296599	Displacement of FAM-p53TAD peptide from N-terminal 8x His-tagged human MDM2 (25 to 108 residues) expressed in Escherichia coli BL21 (DE3) after 30 mins by fluorescence polarization assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1908071	Inhibition of GST-tagged MDM4/Biotin-tagged p53 interaction (unknown origin) incubated for 40 mins by TR-FRET assay
AID503042	Induction of apoptosis in human MCF7 cells co-transfected with 53BP1-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1633982	Inhibition of MDM2/P53 interaction in human A549 cells assessed as ratio of p53 to GAPDH level at 40 uM after 24 hrs by Western blot analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
AID1908083	Cytotoxicity against human SW480 cells harbouring mutant p53 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID756952	Cytotoxicity against human U937 cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID267242	Binding affinity to MDM2	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
AID1361649	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.37%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID707324	Antiproliferative activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID1908090	Upregulation of p21 expression in human RKO cells incubated for 24 hrs by Western blot analysis
AID684828	Antiproliferative activity against human A549 cells expressing wild type p53 after 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Oct, Volume: 56	Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
AID1908082	Cytotoxicity against human HeLa cells harbouring unstable p53 assessed as cell growth inhibition incubated for 4 days by CCK-8 assay
AID1908089	Upregulation of p53 expression in human RKO cells incubated for 24 hrs by Western blot analysis
AID362384	Binding affinity to human recombinant Mdm2 K98W mutant expressed in Escherichia coli BL21 (DE3) cells by antagonist induced dissociation assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	NMR screening for lead compounds using tryptophan-mutated proteins.
AID1212310	Drug uptake in C57BL/6 mouse adipose tissue at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1366813	Inhibition of MDM2/p53 interaction in human U2OS cells assessed as p53 activation by measuring EGFP-positive cells after 24 hrs by Hoechst 33258 staining based fluorescence microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID707310	Induction of apoptosis in human A549 cells expressing wild type p53 after 48 hrs using annexin V-FITC staining by flow cytometry assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID749325	Cytotoxicity against human A549 cells expressing wild type p53 assessed as growth inhibition after 72 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
AID1212305	Drug uptake in C57BL/6 mouse muscle at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1633968	Inhibition of MDM2/P53 interaction in human A549 cells assessed as ratio of p53 to GAPDH level at 20 uM after 24 hrs by Western blot analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
AID1057110	Cytotoxicity against human H1299 cells after 72 hrs by CellTiterGlo luciferase-based assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.
AID415698	Inhibition of interaction between human DM2(1-549) and p53	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Beta-peptides with improved affinity for hDM2 and hDMX.
AID1366815	Inhibition of MDM2/p53 interaction in human U2OS cells by assessed as p53 activation measuring EGFP-positive cells at 5 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopic analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID1057105	Induction of p53 translocation in human HCT116 cells assessed as protein nuclear to cytosolic ratio at 3.3 uM after 20 hrs by immunofluorescence analysis	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.
AID1212306	Drug uptake in C57BL/6 mouse retina at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID707312	Induction of apoptosis in human A549 cells expressing wild type p53 at 10 uM after 48 hrs using annexin V-FITC staining by flow cytometry assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID1212307	Drug uptake in C57BL/6 mouse brain at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID438431	Induction of p53 in human HCT116 cells coexpressing pp53TA-luc assessed as inhibition of cell proliferation after 8 hrs by firefly/renilla luciferase reporter assay	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID1192746	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID503029	Antiproliferative activity against human A549 cells transfected with 53BP1-targeting iRNA-based shRNA assessed as effect on cellular morphology at 4 uM after 14 days by coomassie staining	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1361659	Antitumor activity against human A549 cells xenografted in BALB/C nude mouse assessed as inhibition of tumor growth at 100 mg/kg, po administered once daily for 21 days starting day 11 after tumor cells implantation	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1565009	Inhibition of MDM2-p53 interaction in human SJSA1 cells expressing wild-type p53 assessed as upregulation of MDM2 expression at 5 uM measured after 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID1296608	Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1565011	Inhibition of MDM2-p53 interaction in human U2OS cells expressing wild-type p53 assessed as upregulation of MDM2 expression at 5 uM measured after 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID755375	Antitumor activity against human MV4-11 cells xenografted in NOD/SCID mouse assessed as tumor growth inhibition at 200 mg/kg/day, po bid administered on day 21 to 24 and day 27 to 30 measured on day 31 relative to control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
AID756920	Induction of apoptosis in human MCF7 cells assessed as accumulation of caspase-3 cleavage product at 50 nM after 24 to 72 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1366820	Inhibition of MDM2/p53 (unknown origin) complex at 10 uM by ELISA	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
AID1238646	Inhibition of mouse MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1503133	Antiproliferative activity in p53 (+/+) human HCT116 cells incubated for 72 hrs by MTS assay
AID1421138	Inhibition of Cy5-labeled p53 derived TFSDLWKLL peptide binding to C-terminal biotin-labelled human MDM2 (2 to 188 residues) by TR-FRET assay	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
AID438437	Inhibition of human p21 deficient HCT116 cell proliferation after 16 hrs by BrdU assay	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID756933	Induction of apoptosis in human MCF7 cells assessed as accumulation at subG1 phase at 3 uM by propidium iodide staining-based FACS analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID684826	Antiproliferative activity against human p53-deficient Saos2 cells after 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Oct, Volume: 56	Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
AID756922	Induction of apoptosis in human MCF7 cells assessed as increase in Bcl-xS expression level at 3 uM after 24 to 72 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID588015	Cytotoxicity against human NGP cells after 72 hrs by sulforhodamine B assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID1212299	Drug uptake in C57BL/6 mouse intestine at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID503027	Antiproliferative activity against human MCF7 cells assessed as appearance of flattened phenotype at 4 uM after 14 days by coomassie staining	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1908026	Upregulation of MDM2 protein expression in human MCF7 cells at 10 uM measured after 24 hrs by Western blot analysis
AID1212303	Drug uptake in C57BL/6 mouse adrenal gland at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID425674	Inhibition of GST-tagged MDM2/His6-tagged p53 interaction by surface plasmon resonance study	2009	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14	Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking.
AID755374	Toxicity in NOD/SCID mouse xenografted with human MV4-11 cells assessed as body weight loss at 200 mg/kg/day, po bid administered on day 21 to 24 and day 27 to 30 measured every 2 days during compound administration relative to control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
AID1387293	Antiproliferative activity against p53 -/- human NCI-H1299 cells incubated for 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
AID707323	Antiproliferative activity against human A549 cells expressing wild type p53 after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID748502	AUClast in mouse at 100 mg/kg, po	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID706601	Inhibition of human MDM2-p53 interaction after 18 hrs by HTRF assay	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-based design of novel inhibitors of the MDM2-p53 interaction.
AID1285802	Inhibition of Flag-tagged p53/GST-tagged DAPK1 (unknown origin) expressed in Escherichia coli BL21 after 1 hr by ELISA microplate reader method	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID707317	Inhibition of p53-MDMX interaction after 1 hr by fluorescence polarization assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID684829	Antiproliferative activity against human p53-deficient NCI-H1299 cells after 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Oct, Volume: 56	Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
AID1908049	Downregulation of MDM4 protein expression in human NCI-H460 cells at 10 uM measured after 24 hrs by Western blot analysis
AID1143672	Induction of apoptosis in human HCT116 cells assessed as accumulation at G1 phase at 50 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 62.5%)	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1503134	Antiproliferative activity in p53 (-/-) human HCT116 cells incubated for 72 hrs by MTS assay
AID749489	Cytotoxicity against human A549 cells expressing wild type p53 after 72 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
AID1238648	Selectivity index, ratio of Ki for dog MDM2 to Ki for human MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1361636	Inhibition of MDM2/P53 interaction in human A549 cells assessed as increase in p53 expression after 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID621850	Growth inhibition of human SJSA1 cells expressing MDM2 by SRB assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
AID1212289	Drug uptake in C57BL/6 mouse spleen at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1249873	Stabilization of p53 in human U2OS cells assessed as intracellular p53 level at 2.5 uM after 12 hrs by Western blotting	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Discovery of Novel Isatin-Based p53 Inducers.
AID1633969	Inhibition of MDM2/P53 interaction in human A549 cells assessed as ratio of p53 to GAPDH level at 10 uM after 24 hrs by Western blot analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
AID756949	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1143673	Induction of apoptosis in human HCT116 cells assessed as accumulation at S phase at 50 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 24.8%)	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1285812	Upregulation of Mdm2 in human MCF7 cells after 24 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID1238645	Inhibition of dog MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1300245	Inhibition of human recombinant His-tagged MDM2 (1 to 118 residues) interaction with FAM-tagged p53-based peptide (unknown origin) incubated for 15 mins by fluorescence polarization assay	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
AID1212287	Drug uptake in C57BL/6 mouse intestine at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1143660	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID756925	Induction of apoptosis in human MCF7 cells assessed as reduction in Bcl-xL expression level at 3 uM after 24 to 72 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1143661	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID438436	Inhibition of human p53 deficient HCT116 cell proliferation after 16 hrs by BrdU assay	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
AID1212298	Drug uptake in C57BL/6 mouse vitreous humor at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1195730	Binding affinity to MDM2 (unknown origin)	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
AID503038	Induction of p21CIP1 expression in irradiated human BJ cells at 3 uM by Western blot analysis	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1212309	Drug uptake in C57BL/6 mouse vitreous humor at 10 mg/kg, iv as single dose measured at 24 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID503031	Induction of cell cycle arrest in human MCF7 cells p53-targeting iRNA-based shRNA assessed as accumulation at S phase at 4 uM after 48 hrs by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID626521	Antitumor activity against p53 deficient human Saos2 cells after 72 hrs by MTT assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
AID1908047	Effect on MDM4 protein expression in human MCF7 cells at 10 uM measured after 24 hrs by Western blot analysis
AID707327	Induction of apoptosis in human A549 cells expressing wild type p53 at 5 uM after 48 hrs using annexin V-FITC staining by flow cytometry assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID684827	Antiproliferative activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Oct, Volume: 56	Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
AID736742	Inhibition of human MDM2 expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell cycle arrest after 42 hrs	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID417066	Binding affinity to MDM2	2008	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22	Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics.
AID1565007	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells expressing wild type p53 at 20 uM measured after 72 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry analysis (Rvb = 6.8 %)	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID684825	Inhibition of MDM2 binding domain assessed as inhibition of p53 binding to MDM2 after 1 hr by fluorescence polarization assay	2012	European journal of medicinal chemistry, Oct, Volume: 56	Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
AID707322	Antiproliferative activity against p53 deficient human NCI-H1299 cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
AID1143665	Induction of apoptosis in human HCT116 cells after 48 hrs by propidium iodide staining-based flow cytometry	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1212286	Cytotoxicity against doxorubicin-resistant human UKF-NB-3 cells after 96 hrs by MTT assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID588008	Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of p21 protein at 1 to 10 uM after 6 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID756859	Inhibition of MDM2-p53 interaction in human SJSA1 cells assessed as MDM2 accumulation after 24 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
AID503035	Induction of CDKN1A gene expression in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA by Western blot analysis	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID243263	Potency against MDM2 (murine double minute-2 gene) binding to p53; Range =100-300 nM	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	p53 Activation by small molecules: application in oncology.
AID1908039	Effect on MDM4 protein expression in human U2OS cells at 10 uM measured after 24 hrs by Western blot analysis
AID503041	Induction of cell cycle arrest in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1415891	Inhibition of 5'-FAM-LTFEHYWAQLTS binding to N-terminal domain of recombinant human MDM2 expressed in Escherichia coli BL21(DE3) after 15 mins by fluorescence polarization assay	2017	MedChemComm, May-01, Volume: 8, Issue:5	Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists
AID1296598	Displacement of FAM-Bid peptide from N-terminal 8x His-tagged Bcl-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) after 30 mins by fluorescence polarization assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID736744	Inhibition of human p53 expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell growth at 10 uM after 42 hrs	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1908091	Upregulation of MDM2 expression in human RKO cells incubated for 24 hrs by Western blot analysis
AID706603	Activity at p53 in human SJSA1 cells assessed as induction of p21 mRNA expression after 7 hrs by qRT-PCR analysis in presence of 10% human serum	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-based design of novel inhibitors of the MDM2-p53 interaction.
AID748500	Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID738713	Antiproliferative activity against human SJSA1 cells expressing wild type p53 after 5 days by MTS assay	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID503030	Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 48 hrs by BrdU incorporation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID588007	Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of p53 protein at 1 to 10 uM after 6 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID587350	Inhibition of human GST-tagged MDMX expressed in Escherichia coli harboring integrated p53-Hmd2 protein assessed as blockade of enzyme-p53 interaction by ELISA assay	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.
AID1212291	Drug uptake in C57BL/6 mouse adipose tissue at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID721248	Inhibition of human p53/MDM2 interaction	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.
AID1300911	Antiproliferative activity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID756947	Cytotoxicity against human C643 cells after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.
AID1387291	Antiproliferative activity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
AID738979	Antiproliferative activity against human HeLa cells harboring p53 mutant at 10 uM after 5 days by MTS assay	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID1296621	Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1143659	Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1361652	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.10%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1656007	Binding affinity to 6xHis-taged MDM2 (unknown origin) expressed in Escherichia coli Gold (DE3) assessed as inhibition constant	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR.
AID1192745	Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID1361629	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1238644	Inhibition of human MDM2 by TR-FRET assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
AID1908059	Upregulation of MDM2 protein expression in human U2OS cells at 10 uM measured after 24 hrs by Western blot analysis
AID1387290	Antiproliferative activity against human SJSA1 cells expressing wild type p53 incubated for 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
AID588018	Cytotoxicity against human Saos2 cells after 72 hrs by sulforhodamine B assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
AID503040	Antiproliferative activity against human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA assessed as effect on cellular morphology at 4 uM after 14 days by coomassie staining	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1296610	Inhibition of MDM2-p53 interaction in human HCT116 p53+/+ cells assessed as upregulation of p21 expression after 12 hrs by immunoblotting method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1361645	Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 5 uM after 48 hrs by flow cytometric analysis (Rvb = 31.18%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1195734	Antitumor activity against human SJSA1 cells xenografted in mouse assessed as tumor growth inhibition at 200 mg/kg, po bid administered for 20 days	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
AID1296622	Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 26%)	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID736738	Inhibition of human MDM2-p53 interaction expressed in Saccharomyces cerevisiae CG379 assessed as reversal of MDM2-dependent inhibition of p53-induced growth inhibition at 10 uM after 42 hrs	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1633978	Inhibition of MDM2/P53 interaction in human RKO cells assessed as ratio of p53 to GAPDH level at 10 uM after 24 hrs by Western blot analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
AID362378	Binding affinity to human wild type Mdm2 by isothermal titration calorimetry	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	NMR screening for lead compounds using tryptophan-mutated proteins.
AID1378961	Inhibition of V1-p53/MDM2-V2 (unknown origin) interaction expressed in human HCT116 p53-/- cells at 10 uM after 20 hrs by biomolecular fluorescence complementation-based flow cytometric analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	In vitro targeting of colon cancer cells using spiropyrazoline oxindoles.
AID1300912	Inhibition of HIF-1 (unknown origin) expressed in human MCF7 cells co-transfected with hypoxia reporter plasmid p(HRE)3-Luc at 20 uM measured under hypoxia condition after 24 hrs by dual-luciferase reporter assay	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID1580651	Antiproliferative activity against human SJSA1 cells expressing wild-type p53 incubated for 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22	Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide.
AID1392511	Antiproliferative activity against human HCT116 p53+/+ cells assessed as growth inhibition after 24 hrs by EdU/Hoechst 33342 staining-based fluorescence analysis	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction.
AID1361630	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID265956	Antiproliferative activity against human LnCAP cell line with wild type p53	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
AID738725	Antiproliferative activity against human SW480 cells harboring p53 mutant at 10 uM after 5 days by MTS assay	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID503043	Induction of p21 expression in irradiated human BJ cells at 3 uM by Western blot analysis	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
AID1285801	Inhibition of Flag-tagged p53/GST-tagged Mdmx (unknown origin) expressed in Escherichia coli BL21 after 1 hr by ELISA microplate reader method	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
AID1057104	Induction of p53 translocation in human HCT116 cells assessed as protein nuclear to cytosolic ratio at 10 uM after 20 hrs by immunofluorescence analysis	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.
AID1361642	Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 1 uM after 48 hrs by flow cytometric analysis (Rvb = 31.18%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID736735	Inhibition of MDM2-p53 interaction in human MCF7 cells assessed as reversal of MDM2-dependent inhibition of p53-induced transcriptional activity at 10 uM after 16 hrs by dual-luciferase reporter gene assay	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1212288	Drug uptake in C57BL/6 mouse liver at 50 to 200 mg/kg, po as single dose measured at 2 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
AID1143667	Induction of apoptosis in human HCT116 cells assessed as accumulation at S phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1392512	Antiproliferative activity against human HCT116 p53-/- cells assessed as growth inhibition after 24 hrs by EdU/Hoechst 33342 staining-based fluorescence analysis	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction.
AID1143666	Induction of apoptosis in human HCT116 cells assessed as accumulation at G1 phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
AID1300909	Antiproliferative activity against human p53-null HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.
AID748503	Cmax in mouse at 100 mg/kg, po	2013	ACS medicinal chemistry letters, May-09, Volume: 4, Issue:5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
AID362382	Binding affinity to human recombinant Mdm2 T101W mutant expressed in Escherichia coli BL21 (DE3) cells by antagonist induced dissociation assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	NMR screening for lead compounds using tryptophan-mutated proteins.
AID736736	Inhibition of human MDM2-p53 interaction expressed in Saccharomyces cerevisiae CG379 assessed as reversal of MDM2-dependent inhibition of p53-induced transcriptional activity at 10 uM after 16 hrs by dual-luciferase reporter gene assay	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1564998	Displacement of 5'FAM-LTFEHYWAQLTS from human recombinant MDMX (18 to 111 residues) expressed in Escherichia coli BL21 (DE3) cells measured after 30 mins by fluorescence polarization assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID749323	Selectivity ratio of IC50 for human p53-null PC3 cells to IC50 for human A549 cells expressing wild type p53	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
AID1565012	Inhibition of MDM2-p53 interaction in human U2OS cells expressing wild-type p53 assessed as upregulation of p21 expression at 5 uM measured after 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2013	Acta crystallographica. Section D, Biological crystallography, Aug, Volume: 69, Issue:Pt 8	The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	135 (19.40)	29.6817
2010's	501 (71.98)	24.3611
2020's	60 (8.62)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (0.14%)	5.53%
Reviews	28 (4.01%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	669 (95.85%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
phosphoserine Phosphoserine: The phosphoric acid ester of serine.	2.1	1	0	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
adenine [no description available]	2.58	2	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
carbamates [no description available]	2.45	2	0	amino-acid anion
coumarin 2H-chromen-2-one: coumarin derivative	2.06	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
cytosine [no description available]	2.25	1	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.49	2	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.08	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glycine [no description available]	2.55	2	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	4.16	3	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.05	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
pteridines [no description available]	2.05	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; pteridines
thymine [no description available]	2.15	1	0	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
toluene methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.	4.88	12	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.79	3	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1,5-dihydroxyisoquinoline 1,5-dihydroxyisoquinoline: structure in first source. isoquinoline-1,5-diol : An isoquinolinol that is isoquinoline in which the hydrogens at positions 1 and 5 are replaced by hydroxy groups.	2.1	1	0	isoquinolinol	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.15	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	2.04	1	0	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	7.63	2	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.52	2	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
berberine [no description available]	7.41	1	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
caffeine [no description available]	2.05	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.1	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.45	2	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.11	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	2.17	1	0	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.17	1	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.08	1	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	2.25	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
3,3'-diindolylmethane 3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist	2.25	1	0	indoles	antineoplastic agent; P450 inhibitor
disulfiram [no description available]	2.13	1	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.07	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.05	1	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	3.36	6	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	2.13	1	0
ifenprodil ifenprodil: NMDA receptor antagonist	2.08	1	0	piperidines
staurosporine aglycone staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor	2.1	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.04	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.11	1	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.07	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	7.5	2	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
nocodazole [no description available]	4.55	5	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	7.46	2	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
entinostat [no description available]	2.53	2	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.03	1	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pifithrin pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source	4.88	12	0	aromatic ketone
4-aminobenzoic acid para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.. 4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.	3.39	6	0	aminobenzoate; aromatic amino-acid anion	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.81	3	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide [no description available]	3.02	4	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.	2.15	1	0	nitrosamine	carcinogenic agent; hepatotoxic agent; mutagen
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	8.68	9	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.13	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	2.05	1	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.1	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.45	2	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.04	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
cytarabine [no description available]	2.8	3	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
caramiphen caramiphen: structure	2.08	1	0	benzenes
dichloroacetic acid [no description available]	2.55	2	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
isatin tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;	2.61	2	0	indoledione	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
1,3-dichloro-2-propanol 1,3-dichloro-2-propanol: RN given refers to cpd with specified locants. 1,3-dichloropropan-2-ol : A secondary alcohol that is isopropanol in which one hydrogen of each methyl group is substituted by a chlorine. A liquid at room temperature (melting point -4degreeC, boiling point 174degreeC at 760 mm Hg), it is used as a solvent for hard resins and nitrocellulose.	2.17	1	0	organochlorine compound; secondary alcohol	cross-linking reagent; protic solvent
alpha-chlorohydrin alpha-Chlorohydrin: A chlorinated PROPANEDIOL with antifertility activity in males used as a chemosterilant in rodents.. 3-chloropropane-1,2-diol : A chloropropane-1,2-diol that is propane-1,2-diol substituted by a chloro group at position 3.	2.17	1	0	chloropropane-1,2-diol
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	2.06	1	0	quinuclidines; saturated organic heterobicyclic parent
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	3.03	4	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.08	4	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.13	1	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.07	1	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	3.01	4	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.11	1	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.54	2	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
thiazoles [no description available]	3.19	5	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	3.33	6	0	diazine; pyrazines	Daphnia magna metabolite
hydrazine diamine : Any polyamine that contains two amino groups.	2.17	1	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.1	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
thymidine monophosphate Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).	2.11	1	0	thymidine 5'-monophosphate	fundamental metabolite
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	3.23	5	0
aminoacetonitrile Aminoacetonitrile: Cyanomethylamine.	2.06	1	0
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.08	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	2.17	1	0	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
deoxycytidine [no description available]	3.33	6	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	2.05	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	2.1	1	0
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	3.16	5	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	8.32	6	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.13	1	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.54	2	0	benzenes; phenyl acetates
azoxymethane Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.	2.45	2	0
flubendazole flubendazole: the p-fluoro analog of mebendazole. flubendazole : A member of the class of mebendazole in which the benzoyl group is replaced by a p-fluorobenzoyl group. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.11	1	0	aromatic ketone; benzimidazoles; carbamate ester; organofluorine compound	antinematodal drug; teratogenic agent
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.6	8	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	9.2	16	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
staurosporine [no description available]	2.25	1	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.15	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
brequinar brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.	2.25	1	0	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	3.16	5	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.33	6	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
irinotecan [no description available]	3.39	6	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.17	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
vanadates Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.	2.31	1	0	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol [no description available]	2.11	1	0	stilbenoid
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.07	1	0	organic bromide salt	colorimetric reagent; dye
5-chloro-2'-deoxyuridine [no description available]	2.05	1	0
st 679 [no description available]	2.1	1	0	N-acyl-amino acid
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.1	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	4.18	3	0	1,2,3-triazole
3-deazaneplanocin 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist	2.17	1	0
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.06	1	0	D-glucuronic acid	algal metabolite
triptolide [no description available]	2.04	1	0	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
parthenolide [no description available]	2.05	1	0	germacranolide
ecteinascidin 743 [no description available]	2.11	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.13	1	0
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.15	1	0	abietane diterpenoid	anticoronaviral agent
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	3.01	4	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.1	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
27-hydroxycholesterol (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration.	2.11	1	0	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.49	2	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
perifosine [no description available]	2.05	1	0	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
tariquidar [no description available]	2.69	2	0	benzamides
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	3.31	6	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.21	1	0	abietane diterpenoid
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.21	1	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
erlotinib hydrochloride [no description available]	2.55	2	0	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
lapatinib [no description available]	2.81	3	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	4.4	4	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
nutlin 3 [no description available]	4.08	4	0	stilbenoid
anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.	2.02	1	0	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.21	1	0
2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one: structure in first source	2.1	1	0	cyclic ketone; quinuclidines
pifithrin mu 2-phenylacetylenesulfonamide: induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia cells; also inhibits Hsp70 and autophagy	2.05	1	0	benzenes
2,5-bis(5-hydroxymethyl-2-thienyl)furan [no description available]	5.06	12	0	thiophenes
bortezomib [no description available]	3.47	7	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
nsc 23766 [no description available]	3.13	1	0	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
nsc 146109 (10-methyl-9-anthryl)methyl imidothiocarbamate: a p53 activator with antineoplastic activity; structure in first source	2.06	1	0
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	2.74	3	0
carboplatin [no description available]	7.77	3	0
leptomycin b [no description available]	2.75	3	0
indican [no description available]	2.08	1	0	beta-D-glucoside; exopolysaccharide; indolyl carbohydrate
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.47	2	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	7.08	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.41	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.	2.03	1	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	5.05	12	0	actinomycin	mutagen
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.02	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.74	3	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
chalcone trans-chalcone : The trans-isomer of chalcone.	2.02	1	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.08	1	0	stilbene
s 1033 [no description available]	2.57	2	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
isopropyl thiogalactoside Isopropyl Thiogalactoside: A non-metabolizable galactose analog that induces expression of the LAC OPERON.. isopropyl beta-D-thiogalactopyranoside : An S-glycosyl compound consisting of beta-D-1-thiogalactose having an isopropyl group attached to the anomeric sulfur.	2.47	2	0	S-glycosyl compound
fludarabine [no description available]	8.16	5	0	purine nucleoside
sesquiterpenes [no description available]	2.05	1	0
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	7.07	1	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
tenovin-1 tenovin-1: a SIRT1 inhibitor with antineoplastic activity; structure in first source	2.11	1	0	thioureas
5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one [no description available]	2.13	1	0
sj 172550 SJ 172550: has antineoplastic activity; structure in first source	2.11	1	0
nbd 556 [no description available]	3.13	1	0
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.49	2	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
tempo TEMPO: structure. TEMPO : A member of the class of aminoxyls that is piperidine that carries an oxidanediyl group at position 1 and methyl groups at positions 2, 2, 6, and 6, respectively.	2.08	1	0	aminoxyls; piperidines	catalyst; ferroptosis inhibitor; radical scavenger
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide: partial structure given in first source; endothelium-derived relaxing factor antagonist	2.04	1	0
tamoxifen [no description available]	2.48	2	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
p5091 P5091: inhibits ubiquitin-specific protease 7; structure in first source	2.17	1	0
sirtinol [no description available]	2.07	1	0	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.48	2	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
rtki cpd RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors	2.08	1	0
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.06	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
epi 001 EPI 001: an antineoplastic agent and androgen receptor antagonist; structure in first source. bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether : The (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) diether of bisphenol A; a small molecule that inhibits transactivation of the AR amino-terminal domain (NTD).	3.35	1	0	diether; organochlorine compound	androgen antagonist
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.13	1	0
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.04	1	0	long-chain fatty acid
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	2.05	1	0	organic cation; xanthene dye	fluorochrome
ku 55933 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source	2.81	3	0
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	2.47	2	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
genistein [no description available]	2.05	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
butein [no description available]	2.04	1	0	chalcones; polyphenol	antineoplastic agent; antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor; geroprotector; hypoglycemic agent; plant metabolite; radiosensitizing agent; tyrosine kinase inhibitor
garcinol garcinol: from stem bark of Garcinia huillensis; has chemotherapeutic activity against gram-positive & gram-negative cocci, mycobacteria & fungi	2.06	1	0
zearalenone Zearalenone: (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione. One of a group of compounds known under the general designation of resorcylic acid lactones. Cis, trans, dextro and levo forms have been isolated from the fungus Gibberella zeae (formerly Fusarium graminearum). They have estrogenic activity, cause toxicity in livestock as feed contaminant, and have been used as anabolic or estrogen substitutes.. zearalenone : A macrolide comprising a fourteen-membered lactone fused to 1,3-dihydroxybenzene; a potent estrogenic metabolite produced by some Giberella species.	2.25	1	0	macrolide; resorcinols	fungal metabolite; mycoestrogen
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.08	1	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
myricetin [no description available]	2.21	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.46	7	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
ro26-4550 [no description available]	3.17	1	0
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide : A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycine	4.06	2	0	D-leucine derivative; dichlorobenzene; furoic acid; glycine derivative; guanidines; pyrazolylpiperidine
nutlin 2 [no description available]	4.59	4	0
kn 93 KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.	2.1	1	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	2.05	1	0
spd-304 SPD-304: structure in first source	3.13	1	0
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.08	1	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
su 11248 [no description available]	2.31	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
jnj-7706621 [no description available]	3.87	2	0	sulfonamide
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.21	1	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
flavokawain a flavokawain A: from kava extract, induces apoptosis in bladder cancer cells; structure in first source	2.17	1	0	chalcones
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	2.1	1	0	metalloid atom; pnictogen	micronutrient
geldanamycin [no description available]	2.46	2	0
l 685458 L 685458: a gamma-secretase inhibitor; structure in first source. L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease.	2.05	1	0	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic
vx680 [no description available]	2.97	4	0	N-arylpiperazine
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.11	1	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
axitinib [no description available]	2.21	1	0	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
tanespimycin CP 127374: analog of herbimycin A	2.06	1	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	2.11	1	0	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
staurosporine staurosporinium : Conjugate acid of staurosporine.	3.36	2	0	ammonium ion derivative
sl 327 SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.	2.06	1	0
gambogic acid gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer	2.08	1	0	pyranoxanthones	metabolite
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.04	1	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
avn 944 VX-944: small molecule selective noncompetitive inhibitor of both isoforms of human inosine monophosphate dehydrogenase; induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway	2.05	1	0
motexafin gadolinium [no description available]	2.05	1	0
bibr 1532 [no description available]	2.31	1	0
cp 31398 CP 31398: structure in first source	2.52	2	0
nutlin 1 nutlin 1: an MDM2 antagonist; structure in first source	4.91	6	0
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.13	1	0	organic cation
azd 6244 AZD 6244: a MEK inhibitor	2.05	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ningalin b ningalin B: structure in first source	2.25	1	0
abt-737 [no description available]	4.78	9	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
px 478 2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide: inhibits hypoxia-inducible factor-1alpha	2.25	1	0
fg-4592 roxadustat: structure in first source. roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH).	2.25	1	0	aromatic ether; isoquinolines; N-acylglycine	EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
bi 2536 [no description available]	2.05	1	0
MI-63 MI-63 : An azaspiro compound resulting from the formal fusion of position 3 of 6-chloro-oxindole with position 3 of (2R,3SS5S)-3-(3-chloro-2-fluorophenyl)-5-(2,2-dimethylpropyl)-N-[2-(morpholin-4-yl)ethyl]pyrrolidine-2-carboxamide. It is a potent inhibitor of the MDM2-p53 interaction.	2.97	4	0	azaspiro compound; monochlorobenzenes; monofluorobenzenes; morpholines; oxindoles; pyrrolidines; secondary carboxamide	apoptosis inducer
fi-700 FI-700: FLT3 inhibitor that selectively suppresses the growth of leukemia cells with FLT3 mutations; structure in first source	2.46	2	0
jnj 26854165 [no description available]	2.15	1	0
mdv 3100 [no description available]	3.35	1	0	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.46	2	0
hbx 41108 HBX 41,108: inhibits USP7 ubiquitin protease; structure in first source	2.17	1	0
kn 92 KN 92: KN 93 isomer; a calcium/calmodulin-dependent kinase II inhibitor;	2.1	1	0
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	2.25	1	0	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
nutlin-3b [no description available]	2.07	1	0	Nutlin; piperazinone	anticoronaviral agent
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	2.06	1	0
2,3,4,10-tetrahydro-7,10-dimethyl-2,4-dioxobenzo(g)pteridine [no description available]	3.17	1	0	flavin
olaparib [no description available]	2.13	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
thiostrepton Thiostrepton: One of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders.. thiostrepton : A heterodetic cyclic peptide, in which the cyclisation step involves a formal lactonisation between the carboxy group of a quinaldic acid-based residue and a secondary alcohol. An antibiotic that inhibits bacterial protein synthesis. Also acts as an antitumor agent.	2.1	1	0
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	2.25	1	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.81	3	0	benzazepine
tenovin-6 tenovin-6 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(dimethylamino)pentanoic acid with the aromatic amino group of N-[(4-aminophenyl)carbamothioyl]-4-tert-butylbenzamide.	2.07	1	0	monocarboxylic acid amide; tertiary amino compound; thioureas	antineoplastic agent; p53 activator; Sir2 inhibitor
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.13	1	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.54	2	0	piperazines
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.15	1	0	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	2.21	1	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
plx4032 [no description available]	4.39	4	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
piperidines Piperidines: A family of hexahydropyridines.	2.51	2	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.49	2	0
dabrafenib [no description available]	2.25	1	0	1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide	anticoronaviral agent; antineoplastic agent; B-Raf inhibitor
yk 4-279 YK 4-279: an antineoplastic agent that inhibits EWS-FLI1 oncoprotein; structure in first source	2.1	1	0	aromatic ketone
pb 12 [no description available]	3.21	1	0
gx 15-070 obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma	2.11	1	0
apr-246 eprenetapopt: works in tandem with cisplatin to cause apoptosis of tumor cells; structure in first source	2.06	1	0
nvp-cgm097 NVP-CGM097: an MDM2 and HDM2 inhibitor; structure in first source	3.65	2	0
rg7388 RG7388: structure in first source	3.39	6	0
sar405838 SAR405838: an inhibitor of the interaction of MDM2 and p53; has antineoplastic activity; structure in first source	4.99	6	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.05	1	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.07	1	0
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.06	1	0	benzenes; hydroxycoumarin; methyl ketone
(1S,2R)-2-[[(1S)-1-[(1,3-dioxo-2-isoindolyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-oxomethyl]-1-cyclohexanecarboxylic acid LH601A: inhibits the interaction between KEAP1 and NRF2; structure in first source	3.35	1	0	phthalimides
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.06	1	0
rg7112 [no description available]	5.03	6	0
amg 232 [no description available]	4.04	3	0
gsk2830371 GSK2830371: inhibits Wip1 phosphatase; structure in first source	3.23	5	0
selinexor selinexor: inhibits karyopherin XPO1	2.17	1	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	3.17	5	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.49	2	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	3.46	7	0
oridonin [no description available]	2.15	1	0
apicidin apicidin: structure in first source	2.07	1	0
deoxyguanosine [no description available]	2.15	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.05	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.48	2	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.47	2	0	dacarbazine
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.15	1	0	guanosines	biomarker
mi-219 MI-219: an MDM2 inhibitor; structure in first source	2.8	3	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.54	2	0
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.04	1	0

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	8.39	57	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	8.39	57	0
Bone Cancer [description not available]	3.88	11	0
Osteogenic Sarcoma [description not available]	4.39	19	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.88	11	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	4.39	19	0
Degenerative Diseases, Central Nervous System [description not available]	2.99	1	0
Bacterial Disease [description not available]	2.99	1	0
Diseases of Immune System [description not available]	2.99	1	0
Viral Diseases [description not available]	2.99	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	2.99	1	0
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	2.99	1	0
Virus Diseases A general term for diseases caused by viruses.	2.99	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.76	3	0
Cancer of Lung [description not available]	4.55	22	0
Lung Neoplasms Tumors or cancer of the LUNG.	4.55	22	0
Experimental Neoplasms [description not available]	2.98	4	0
Breast Cancer [description not available]	10.72	29	0
Breast Neoplasms Tumors or cancer of the human BREAST.	5.72	29	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	4.78	6	0
Cancer of Prostate [description not available]	4.62	9	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	4.62	9	0
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.68	25	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Adenocarcinoma Of Kidney [description not available]	3.02	4	0
Cancer of Kidney [description not available]	3.19	5	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	3.02	4	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	3.19	5	0
Cancer of Pancreas [description not available]	3.06	4	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	3.06	4	0
Cognitive Decline [description not available]	2.41	1	0
Fra(X) Syndrome [description not available]	2.61	2	0
Fragile X Syndrome A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)	2.61	2	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.41	1	0
Infections, Chlamydia [description not available]	2.41	1	0
Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA.	2.41	1	0
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	2.9	2	0
Cancer of Esophagus [description not available]	3.01	3	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	3.01	3	0
Age-Related Macular Degeneration [description not available]	7.57	2	0
Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.	7.57	2	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	6.43	24	0
Hepatocellular Carcinoma [description not available]	3.89	11	0
Cancer of Liver [description not available]	3.8	10	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.89	11	0
Liver Neoplasms Tumors or cancer of the LIVER.	3.8	10	0
Anoxemia [description not available]	4.24	6	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	9.24	6	0
Atypical Lipomatous Tumor [description not available]	3.34	6	0
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	3.34	6	0
Adenocarcinoma, Basal Cell [description not available]	3.05	4	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.05	4	0
Autoimmune Diabetes [description not available]	2.61	2	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.61	2	0
Malignant Melanoma [description not available]	6.4	20	0
Cancer of Skin [description not available]	3.8	10	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	6.4	20	0
Skin Neoplasms Tumors or cancer of the SKIN.	3.8	10	0
Abnormalities, Congenital, Nervous System [description not available]	2.25	1	0
Autoimmune Diseases of the Nervous System Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME).	2.25	1	0
Astrocytoma, Grade IV [description not available]	3.51	7	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	8.51	7	0
Colorectal Cancer [description not available]	3.36	6	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.36	6	0
Cancer of Colon [description not available]	3.93	12	0
Colonic Neoplasms Tumors or cancer of the COLON.	3.93	12	0
Benign Neoplasms, Brain [description not available]	3.37	6	0
Glial Cell Tumors [description not available]	2.52	2	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	3.37	6	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.52	2	0
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	8.27	5	0
Acute Myelogenous Leukemia [description not available]	5.85	21	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	5.85	21	1
Pulmonary Arterial Hypertension A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.	2.31	1	0
Acute Lymphoid Leukemia [description not available]	3.21	5	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	3.21	5	0
Cancer of Stomach [description not available]	2.83	3	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.83	3	0
Carcinoma, Epidermoid [description not available]	2.78	3	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.78	3	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	3.69	9	0
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.15	1	0
Experimental Hepatoma [description not available]	2.15	1	0
Malignant Mesothelioma [description not available]	7.82	3	0
Neoplasms, Pleural [description not available]	2.52	2	0
Diabetic Glomerulosclerosis [description not available]	2.15	1	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.15	1	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	3.46	2	0
Carcinoma, Anaplastic [description not available]	4.23	6	0
Cancer of Nasopharynx [description not available]	3.46	2	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	4.23	6	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	3.46	2	0
Lung Adenocarcinoma [description not available]	2.57	2	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	2.57	2	0
Cancer of Intestines [description not available]	2.17	1	0
Intestinal Neoplasms Tumors or cancer of the INTESTINES.	2.17	1	0
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	2.17	1	0
Dysplastic Nevus Syndrome, Hereditary [description not available]	2.61	2	0
Disease Exacerbation [description not available]	3.18	5	0
Adrenocortical Carcinoma A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.	7.17	1	0
Cirrhosis [description not available]	2.84	3	0
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	2.17	1	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.84	3	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.17	1	0
Carcinoma, Mucoepidermoid A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)	2.17	1	0
Carcinoma, Non-Small Cell Lung [description not available]	3.04	4	0
Eperythrozoonosis [description not available]	2.17	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.04	4	0
Eye Disorders [description not available]	2.17	1	0
Innate Inflammatory Response [description not available]	3.02	4	0
Eye Diseases Diseases affecting the eye.	2.17	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.02	4	0
Neurilemoma [description not available]	2.17	1	0
Neurilemmoma A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)	2.17	1	0
Leucocythaemia [description not available]	4.11	5	0
Acute Disease Disease having a short and relatively severe course.	3.16	5	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	4.11	5	0
Carcinoma, Ductal, Pancreatic [description not available]	2.21	1	0
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.21	1	0
Coronary Artery Stenosis [description not available]	2.21	1	0
Coronary Stenosis Narrowing or constriction of a coronary artery.	2.21	1	0
Pulmonary Hypertension [description not available]	7.08	1	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.08	1	0
Alloxan Diabetes [description not available]	2.51	2	0
Metastase [description not available]	5.28	6	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	5.28	6	0
Sarcoma, Epithelioid [description not available]	3.01	4	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	3.01	4	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	4.66	26	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	4.66	26	0
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.51	2	0
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.51	2	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.08	1	0
Angiogenesis, Pathologic [description not available]	3.89	4	0
Collodion Baby Syndrome [description not available]	2.1	1	0
Keratoderma Blennorrhagicum [description not available]	2.1	1	0
Keratosis Any horny growth such as a wart or callus.	2.1	1	0
Ichthyosis, Lamellar A chronic, congenital ichthyosis inherited as an autosomal recessive trait. Infants are usually born encased in a collodion membrane which sheds within a few weeks. Scaling is generalized and marked with grayish-brown quadrilateral scales, adherent at their centers and free at the edges. In some cases, scales are so thick that they resemble armored plate.	2.1	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.08	1	0
Hematologic Malignancies [description not available]	4.46	3	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	4.46	3	0
Kaposi Sarcoma [description not available]	2.76	3	0
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	2.76	3	0
Cancer of Endometrium [description not available]	2.49	2	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.49	2	0
Ewing Sarcoma [description not available]	7.99	4	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	2.99	4	0
Tetraploid [description not available]	2.48	2	0
B16 Melanoma [description not available]	3.19	5	0
Cancer of Ovary [description not available]	3.35	6	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.35	6	0
Verruca [description not available]	2.1	1	0
Molluscum Contagiosum A common, benign, usually self-limited viral infection of the skin and occasionally the conjunctivae by a poxvirus (MOLLUSCUM CONTAGIOSUM VIRUS). (Dorland, 27th ed)	2.1	1	0
Warts Benign epidermal proliferations or tumors; some are viral in origin.	2.1	1	0
Infections, Plasmodium [description not available]	2.11	1	0
Plasmodium falciparum Malaria [description not available]	2.11	1	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	2.11	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.11	1	0
Aneuploid [description not available]	2.48	2	0
Invasiveness, Neoplasm [description not available]	2.78	3	0
Lymphoma, Primary Effusion A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.	2.78	3	0
Cancer of the Retina [description not available]	3.89	4	0
Eye Cancer, Retinoblastoma [description not available]	4.57	9	0
Retinoblastoma A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)	9.57	9	0
Blast Phase [description not available]	2.76	3	0
Granulocytic Leukemia, Chronic [description not available]	2.11	1	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	2.76	3	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.11	1	0
Local Neoplasm Recurrence [description not available]	2.13	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.11	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.11	1	0
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	2.13	1	0
Germinoblastoma [description not available]	3.32	6	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	8.32	6	0
Adjuvant Arthritis [description not available]	2.13	1	0
Rheumatoid Arthritis [description not available]	2.13	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.13	1	0
Thrombopenia [description not available]	2.13	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.13	1	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	2.13	1	0
Acute Confusional Senile Dementia [description not available]	2.13	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.13	1	0
Cystic Kidney Diseases [description not available]	2.13	1	0
Cyst [description not available]	2.13	1	0
Kidney Diseases, Cystic A heterogeneous group of hereditary and acquired disorders in which the KIDNEY contains one or more CYSTS unilaterally or bilaterally (KIDNEY, CYSTIC).	2.13	1	0
Kahler Disease [description not available]	3.31	6	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	3.31	6	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.78	3	0
Anaplastic Ependymoma [description not available]	2.13	1	0
Ependymoma Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)	2.13	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.78	3	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	2.98	4	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	2.98	4	0
Cardiac Diseases [description not available]	2.15	1	0
Cardiovascular Stroke [description not available]	2.15	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.15	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.15	1	0
B Virus Infection [description not available]	2.48	2	0
Acute Liver Injury, Drug-Induced [description not available]	2.15	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.15	1	0
Polyploid [description not available]	2.74	3	0
Synovioma [description not available]	2.05	1	0
Sarcoma, Synovial A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)	2.05	1	0
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	2.44	2	0
Rhabdomyosarcoma 2 [description not available]	2.45	2	0
Rhabdomyosarcoma, Alveolar A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. Alveolar refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)	2.45	2	0
Lung Injury, Acute [description not available]	2.05	1	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.05	1	0
African Lymphoma [description not available]	2.74	3	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	2.74	3	0
Muscle Tissue Neoplasms [description not available]	2.05	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	2.05	1	0
Cancer of Testis [description not available]	2.46	2	0
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	2.46	2	0
Carcinoma, Embryonal A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)	2.05	1	0
Rhabdomyosarcoma, Embryonal A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)	2.05	1	0
ATLL [description not available]	2.05	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	2.05	1	0
Anaplastic Large-Cell Lymphoma [description not available]	2.05	1	0
Lymphoma, Large-Cell, Anaplastic A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called hallmark cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.	2.05	1	0
Epithelial Neoplasms [description not available]	2.05	1	0
Granulocytic Leukemia [description not available]	2.97	4	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.97	4	0
Female Genital Neoplasms [description not available]	2.05	1	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	2.05	1	0
Cholangiocellular Carcinoma [description not available]	2.05	1	0
Bile Duct Cancer [description not available]	2.05	1	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	2.05	1	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	2.05	1	0
Brill-Symmers Disease [description not available]	2.05	1	0
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	2.05	1	0
Cancer of Larynx [description not available]	2.05	1	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.05	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.97	1	0
Mole, Skin [description not available]	2.05	1	0
Anemia, Macrocytic Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).	2.06	1	0
Dysmyelopoietic Syndromes [description not available]	2.06	1	0
Anemia, Congenital Hypoplastic, Of Blackfan And Diamond [description not available]	2.06	1	0
Chromosome Deletion Actual loss of portion of a chromosome.	2.76	3	0
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	2.06	1	0
Anemia, Diamond-Blackfan A rare congenital hypoplastic anemia that usually presents early in infancy. The disease is characterized by a moderate to severe macrocytic anemia, occasional neutropenia or thrombocytosis, a normocellular bone marrow with erythroid hypoplasia, and an increased risk of developing leukemia. (Curr Opin Hematol 2000 Mar;7(2):85-94)	2.06	1	0
Cancer of Head [description not available]	2.06	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.06	1	0
Chromosomal Translocation [description not available]	2.06	1	0
Diffuse Large B-Cell Lymphoma [description not available]	7.06	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	2.06	1	0
Neointima The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.	2.06	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.06	1	0
Fibroid [description not available]	2.47	2	0
Cancer of the Uterus [description not available]	2.47	2	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	2.47	2	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.47	2	0
Intraocular Pressure The pressure of the fluids in the eye.	2.06	1	0
Ectopic Ossification [description not available]	2.06	1	0
17p11.2 Monosomy [description not available]	2.07	1	0
Smith-Magenis Syndrome Complex neurobehavioral disorder characterized by distinctive facial features (FACIES), developmental delay and INTELLECTUAL DISABILITY. Behavioral phenotypes include sleep disturbance, maladaptive, self-injurious and attention-seeking behaviors. The sleep disturbance is linked to an abnormal circadian secretion pattern of MELATONIN. The syndrome is associated with de novo deletion or mutation and HAPLOINSUFFICIENCY of the retinoic acid-induced 1 protein on chromosome 17p11.2.	2.07	1	0
Uveal Neoplasms Tumors or cancer of the UVEA.	2.07	1	0
Libman-Sacks Disease [description not available]	2.06	1	0
Glomerulonephritis, Lupus [description not available]	2.06	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	2.06	1	0
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	2.06	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.47	2	0
Leukemia, Pre-B-Cell [description not available]	2.07	1	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	2.07	1	0
Acute Kidney Failure [description not available]	2.07	1	0
Injury, Ischemia-Reperfusion [description not available]	2.07	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.07	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	2.07	1	0
Cutaneous T-Cell Lymphoma [description not available]	7.07	1	0
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	2.07	1	0
Erythroderma, Sezary [description not available]	2.07	1	0
Sezary Syndrome A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).	2.07	1	0
Peritoneal Carcinomatosis [description not available]	2.08	1	0
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	2.08	1	0
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	2.07	1	0
Benign Cerebellar Neoplasms [description not available]	2.07	1	0
Gastrointestinal Stromal Neoplasm [description not available]	2.07	1	0
Cancer of Gastrointestinal Tract [description not available]	2.07	1	0
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	2.07	1	0
Erythremia [description not available]	2.48	2	0
Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.	2.48	2	0
Proliferative Vitreoretinopathy [description not available]	2.07	1	0
Retinal Pigment Epithelial Detachment [description not available]	2.07	1	0
Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).	2.07	1	0
Vitreoretinopathy, Proliferative Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes.	2.07	1	0
Carcinoma, Colloid [description not available]	2.08	1	0
Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)	2.08	1	0
Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)	2.08	1	0
B-Cell Lymphoma [description not available]	2.45	2	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.45	2	0
Cancer of Eye [description not available]	2.46	2	0
Cancer, Radiation-Induced [description not available]	2.08	1	0
Diathesis [description not available]	2.07	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.07	1	0
Granuloma, Hodgkin [description not available]	2.44	2	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2.44	2	0
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	2.03	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.03	1	0
Abnormalities, Autosome [description not available]	2.04	1	0
Leukemia, Lymphocytic [description not available]	2.04	1	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	2.04	1	0

nutlin-3a

Description

Cross-References

Synonyms (71)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (348)

Molecular Functions (92)

Ceullar Components (39)

Bioassays (378)

Research

Studies (696)

Market Indicators

Research Demand Index: 35.84

Study Types

nutlin-3a

Description

Cross-References

Synonyms (71)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (348)

Molecular Functions (92)

Ceullar Components (39)

Bioassays (378)

Research

Studies (696)

Market Indicators

Research Demand Index: 35.84

Study Types

Related Drugs (263)

Related Conditions (303)